Neurochemical Research

, Volume 36, Issue 9, pp 1669–1676

Lipid Composition of Whole Brain and Cerebellum in Hurler Syndrome (MPS IH) Mice

  • Karie A. Heinecke
  • Brandon N. Peacock
  • Bruce R. Blazar
  • Jakub Tolar
  • Thomas N. Seyfried
Original Paper

Abstract

Hurler syndrome (MPS IH) is caused by a mutation in the gene encoding alpha-L-iduronidase (IDUA) and leads to the accumulation of partially degraded glycosaminoglycans (GAGs). Ganglioside content is known to increase secondary to GAG accumulation. Most studies in organisms with MPS IH have focused on changes in gangliosides GM3 and GM2, without the study of other lipids. We evaluated the total lipid distribution in the whole brain and cerebellum of MPS IH (Idua−/−) and control (Idua+/?) mice at 6 months and at 12 months of age. The content of total sialic acid and levels of gangliosides GM3, GM2, and GD3 were greater in the whole brains of Idua−/− mice then in Idua+/? mice at 12 months of age. No other significant lipid differences were found in either whole brain or in cerebellum at either age. The accumulation of ganglioside GD3 suggests that neurodegeneration occurs in the Idua−/− mouse brain, but not to the extent seen in human MPS IH brain.

Keywords

Hurler syndrome MPS IH Mouse model Gangliosides Lipids GD3 

References

  1. 1.
    Bach G, Friedman R, Weissmann B et al (1972) The defect in the Hurler and Scheie syndromes: deficiency of -L-iduronidase. Proc Natl Acad Sci U S A 69:2048–2051PubMedCrossRefGoogle Scholar
  2. 2.
    Fuller M, Brooks DA, Evangelista M et al (2005) Prediction of neuropathology in mucopolysaccharidosis I patients. Mol Genet Metab 84:18–24PubMedCrossRefGoogle Scholar
  3. 3.
    Sifuentes M, Doroshow R, Hoft R et al (2007) A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years. Mol Genet Metab 90:171–180PubMedCrossRefGoogle Scholar
  4. 4.
    Kelly TE (1976) The mucopolysaccharidoses and mucolipidoses. Clin Orthop Relat Res 116–133Google Scholar
  5. 5.
    Brante G (1952) Gargoylism; a mucopolysaccharidosis. Scand J Clin Lab Invest 4:43–46PubMedCrossRefGoogle Scholar
  6. 6.
    Leroy JG, Crocker AC (1966) Clinical definition of the Hurler-Hunter phenotypes. A review of 50 patients. Am J Dis Child 112:518–530PubMedGoogle Scholar
  7. 7.
    Terlato NJ, Cox GF (2003) Can mucopolysaccharidosis type I disease severity be predicted based on a patient’s genotype? A comprehensive review of the literature. Genet Med 5:286–294PubMedCrossRefGoogle Scholar
  8. 8.
    MacBrinn M, Okada S, Woollacott M et al (1969) Beta-galactosidase deficiency in the hurler syndrome. N Engl J Med 281:338–343PubMedCrossRefGoogle Scholar
  9. 9.
    Abraham J, Chakrapani B, Singh M et al (1969) Hurler’s disease: a clinical and biochemical study of a case. Indian J Med Res 57:1761–1766PubMedGoogle Scholar
  10. 10.
    Crawfurd M, Dean MF, Hunt DM et al (1973) Early prenatal diagnosis of Hurler’s syndrome with termination of pregnancy and confirmatory findings on the fetus. J Med Genet 10:144–153PubMedCrossRefGoogle Scholar
  11. 11.
    Ellis RW (1936) Gargoylism (chondro-osteo-dystrophy, corneal opacities, hepatosplenomegaly, and mental deficiency). Proc R Soc Med 30:158–160PubMedGoogle Scholar
  12. 12.
    Jervis GA (1942) Familial mental deficiency akin to amaurotic idiocy and gargoylism. An apparently new type. Arch Neurol Psychiatry 47:943–961Google Scholar
  13. 13.
    Booth DA, Goodwin H, Cumings JN (1966) Abnormal gangliosides in Tay-Sachs disease, Niemann-Pick’s disease, and gargoylism. J Lipid Res 7:337–340PubMedGoogle Scholar
  14. 14.
    Clausen J, Dyggve HV, Melchior JC et al (1967) Chemical studies in gargoylism. Arch Dis Child 42:62–69PubMedCrossRefGoogle Scholar
  15. 15.
    Constantopoulos G, Dekaban AS (1978) Neurochemistry of the mucopolysaccharidoses: brain lipids and lysosomal enzymes in patients with four types of mucopolysaccharidosis and in normal controls. J Neurochem 30:965–973PubMedCrossRefGoogle Scholar
  16. 16.
    Ledeen R, Salsman K, Gonatas J et al (1965) Structure Comparison of the major monosialogangliosides from brains of normal human, gargoylism, and late infantile systemic lipidosis. I. J Neuropathol Exp Neurol 24:341–351PubMedCrossRefGoogle Scholar
  17. 17.
    Loeb H, Tondeur M, Toppet M et al (1969) Clinical, biochemical and ultrastructural studies of an atypical form of mucopolysaccharidosis. Acta Paediatr Scand 58:220–228PubMedCrossRefGoogle Scholar
  18. 18.
    Lee C, Dineen TE, Brack M et al (1993) The mucopolysaccharidoses: characterization by cranial MR imaging. AJNR Am J Neuroradiol 14:1285–1292PubMedGoogle Scholar
  19. 19.
    Clarke LA, Russell CS, Pownall S et al (1997) Murine mucopolysaccharidosis type I: targeted disruption of the murine alpha-L-iduronidase gene. Hum Mol Genet 6:503–511PubMedCrossRefGoogle Scholar
  20. 20.
    Haskins ME, Jezyk PF, Desnick RJ et al (1979) Alpha-L-iduronidase deficiency in a cat: a model of mucopolysaccharidosis I. Pediatr Res 13:1294–1297PubMedGoogle Scholar
  21. 21.
    Spellacy E, Shull RM, Constantopoulos G et al (1983) A canine model of human alpha-L-iduronidase deficiency. Proc Natl Acad Sci U S A 80:6091–6095PubMedCrossRefGoogle Scholar
  22. 22.
    Russell C, Hendson G, Jevon G et al (1998) Murine MPS I: insights into the pathogenesis of Hurler syndrome. Clin Genet 53:349–361PubMedCrossRefGoogle Scholar
  23. 23.
    Ciron C, Desmaris N, Colle MA et al (2006) Gene therapy of the brain in the dog model of Hurler’s syndrome. Ann Neurol 60:204–213PubMedCrossRefGoogle Scholar
  24. 24.
    Constantopoulos G, Shull RM, Hastings N et al (1985) Neurochemical characterization of canine alpha-L-iduronidase deficiency disease (model of human mucopolysaccharidosis I). J Neurochem 45:1213–1217PubMedCrossRefGoogle Scholar
  25. 25.
    Desmaris N, Verot L, Puech JP et al (2004) Prevention of neuropathology in the mouse model of Hurler syndrome. Ann Neurol 56:68–76PubMedCrossRefGoogle Scholar
  26. 26.
    Ellinwood NM, Colle MA, Weil MA et al (2007) Bone marrow transplantation for feline mucopolysaccharidosis I. Mol Genet Metab 91:239–250PubMedCrossRefGoogle Scholar
  27. 27.
    Garcia-Rivera MF, Colvin-Wanshura LE, Nelson MS et al (2007) Characterization of an immunodeficient mouse model of mucopolysaccharidosis type I suitable for preclinical testing of human stem cell and gene therapy. Brain Res Bull 74:429–438PubMedCrossRefGoogle Scholar
  28. 28.
    Kakkis ED, Schuchman E, He X et al (2001) Enzyme replacement therapy in feline mucopolysaccharidosis I. Mol Genet Metab 72:199–208PubMedCrossRefGoogle Scholar
  29. 29.
    McGlynn R, Dobrenis K, Walkley SU (2004) Differential subcellular localization of cholesterol, gangliosides, and glycosaminoglycans in murine models of mucopolysaccharide storage disorders. J Comp Neurol 480:415–426PubMedCrossRefGoogle Scholar
  30. 30.
    Shull RM, Helman RG, Spellacy E et al (1984) Morphologic and biochemical studies of canine mucopolysaccharidosis I. Am J Pathol 114:487–495PubMedGoogle Scholar
  31. 31.
    Ledeen R (1983) Gangliosides. In: Lajtha A (ed) Handbook of neurochemistry, vol 3. Plenum Publishing, New York, pp 41–90Google Scholar
  32. 32.
    Seyfried TN, Bernard DJ, Yu RK (1984) Cellular distribution of gangliosides in the developing mouse cerebellum: analysis using the staggerer mutant. J Neurochem 43:1152–1162PubMedCrossRefGoogle Scholar
  33. 33.
    Seyfried TN, Miyazawa N, Yu RK (1983) Cellular localization of gangliosides in the developing mouse cerebellum: analysis using the weaver mutant. J Neurochem 41:491–505PubMedCrossRefGoogle Scholar
  34. 34.
    Chou DK, Flores S, Jungalwala FB (1990) Identification of disialosyl paragloboside and O-acetyldisialosyl paragloboside in cerebellum and embryonic cerebrum. J Neurochem 54:1598–1607PubMedCrossRefGoogle Scholar
  35. 35.
    Furuya S, Irie F, Hashikawa T et al (1994) Ganglioside GD1 alpha in cerebellar Purkinje cells. Its specific absence in mouse mutants with Purkinje cell abnormality and altered immunoreactivity in response to conjunctive stimuli causing long-term desensitization. J Biol Chem 269:32418–32425PubMedGoogle Scholar
  36. 36.
    Seyfried TN, Yu RK (1984) Cellular localization of gangliosides in the mouse cerebellum: analysis using neurological mutants. Adv Exp Med Biol 174:169–181PubMedGoogle Scholar
  37. 37.
    Seyfried TN, Yu RK (1990) Cerebellar ganglioside abnormalities in pcd mutant mice. J Neurosci Res 26:105–111PubMedCrossRefGoogle Scholar
  38. 38.
    Svennerholm L, Bostrom K, Fredman P et al (1989) Human brain gangliosides: developmental changes from early fetal stage to advanced age. Biochim Biophys Acta 1005:109–117PubMedGoogle Scholar
  39. 39.
    Nakatani Y, Yanagisawa M, Suzuki Y et al (2010) Characterization of GD3 ganglioside as a novel biomarker of mouse neural stem cells. Glycobiology 20:78–86PubMedCrossRefGoogle Scholar
  40. 40.
    Seyfried TN, Yu RK, Miyazawa N (1982) Differential cellular enrichment of gangliosides in the mouse cerebellum: analysis using neurological mutants. J Neurochem 38:551–559PubMedCrossRefGoogle Scholar
  41. 41.
    Yu RK, Iqbal K (1979) Sialosylgalactosyl ceramide as a specific marker for human myelin and oligodendroglial perikarya: gangliosides of human myelin, oligodendroglia and neurons. J Neurochem 32:293–300PubMedCrossRefGoogle Scholar
  42. 42.
    Seyfried TN, Yu RK (1985) Ganglioside GD3: structure, cellular distribution, and possible function. Mol Cell Biochem 68:3–10PubMedGoogle Scholar
  43. 43.
    Yu RK, Yen SI (1975) Gangliosides in developing mouse brain myelin. J Neurochem 25:229–232PubMedCrossRefGoogle Scholar
  44. 44.
    Zalc B, Monge M, Dupouey P et al (1981) Immunohistochemical localization of galactosyl and sulfogalactosyl ceramide in the brain of the 30-day-old mouse. Brain Res 211:341–354PubMedCrossRefGoogle Scholar
  45. 45.
    Muse ED, Jurevics H, Toews AD et al (2001) Parameters related to lipid metabolism as markers of myelination in mouse brain. J Neurochem 76:77–86PubMedCrossRefGoogle Scholar
  46. 46.
    Borri PF, Hooghwinkel GJ, Edgar GW (1966) Brain ganglioside pattern in three forms of amaurotic idiocy and in gargoylism. J Neurochem 13:1249–1256PubMedCrossRefGoogle Scholar
  47. 47.
    Ikeno T, Minami R, Tsugawa S et al (1982) Acidic glycosaminoglycans and gangliosides in the brains from four patients with genetic mucopolysaccharidosis. Tohoku J Exp Med 137:253–260PubMedCrossRefGoogle Scholar
  48. 48.
    Baek RC, Kasperzyk JL, Platt FM et al (2008) N-butyldeoxygalactonojirimycin reduces brain ganglioside and GM2 content in neonatal Sandhoff disease mice. Neurochem Int 52:1125–1133PubMedCrossRefGoogle Scholar
  49. 49.
    Hauser EC, Kasperzyk JL, d’Azzo A et al (2004) Inheritance of lysosomal acid beta-galactosidase activity and gangliosides in crosses of DBA/2J and knockout mice. Biochem Genet 42:241–257PubMedCrossRefGoogle Scholar
  50. 50.
    Kasperzyk JL, El-Abbadi MM, Hauser EC et al (2004) N-butyldeoxygalactonojirimycin reduces neonatal brain ganglioside content in a mouse model of GM1 gangliosidosis. J Neurochem 89:645–653PubMedCrossRefGoogle Scholar
  51. 51.
    Seyfried TN, Glaser GH, Yu RK (1978) Cerebral, cerebellar, and brain stem gangliosides in mice susceptible to audiogenic seizures. J Neurochem 31:21–27PubMedCrossRefGoogle Scholar
  52. 52.
    Macala LJ, Yu RK, Ando S (1983) Analysis of brain lipids by high performance thin-layer chromatography and densitometry. J Lipid Res 24:1243–1250PubMedGoogle Scholar
  53. 53.
    Folch J, Lees M, Sloane Stanley GH (1957) A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 226:497–509PubMedGoogle Scholar
  54. 54.
    Svennerholm L (1957) Quantitative estimation of sialic acids. II. A colorimetric resorcinol-hydrochloric acid method. Biochim Biophys Acta 24:604–611PubMedCrossRefGoogle Scholar
  55. 55.
    Ando S, Chang NC, Yu RK (1978) High-performance thin-layer chromatography and densitometric determination of brain ganglioside compositions of several species. Anal Biochem 89:437–450PubMedCrossRefGoogle Scholar
  56. 56.
    Melchior JC, Clausen J, Dyggve HV (1965) The mucopolysaccharisoses. A clinical and biochemical survey. Clin Pediatr (Phila) 4:468–480CrossRefGoogle Scholar
  57. 57.
    Uzman LL (1955) Chemical nature of the storage substance in gargoylism, Hurler-Pfaundler’s disease. AMA Arch Pathol 60:308–318PubMedGoogle Scholar
  58. 58.
    Wherrett JR (1968) Analysis of glycolipids in the Hurler syndrome. Pathol Eur 3:431–439PubMedGoogle Scholar
  59. 59.
    Constantopoulos G, Iqbal K, Dekaban AS (1980) Mucopolysaccharidosis types IH, IS, II, and IIIA: glycosaminoglycans and lipids of isolated brain cells and other fractions from autopsied tissues. J Neurochem 34:1399–1411PubMedCrossRefGoogle Scholar
  60. 60.
    Lekman AY, Hagberg BA, Svennerholm LT (1991) Membrane cerebral lipids in Rett syndrome. Pediatr Neurol 7:186–190PubMedCrossRefGoogle Scholar
  61. 61.
    Levine SM, Seyfried TN, Yu RK et al (1986) Immunocytochemical localization of GD3 ganglioside to astrocytes in murine cerebellar mutants. Brain Res 374:260–269PubMedCrossRefGoogle Scholar
  62. 62.
    Desplats PA, Denny CA, Kass KE et al (2007) Glycolipid and ganglioside metabolism imbalances in Huntington’s disease. Neurobiol Dis 27:265–277PubMedCrossRefGoogle Scholar
  63. 63.
    Walkley SU, Baker HJ, Rattazzi MC et al (1991) Neuroaxonal dystrophy in neuronal storage disorders: evidence for major GABAergic neuron involvement. J Neurol Sci 104:1–8PubMedCrossRefGoogle Scholar
  64. 64.
    Denny CA, Desplats PA, Thomas EA et al. (2010) Cerebellar lipid differences between R6/1 transgenic mice and humans with Huntington’s Disease. J NeurochemGoogle Scholar
  65. 65.
    Bazan NG (2005) Lipid signaling in neural plasticity, brain repair, and neuroprotection. Mol Neurobiol 32:89–103PubMedCrossRefGoogle Scholar
  66. 66.
    Koudinov AR, Koudinova NV (2001) Essential role for cholesterol in synaptic plasticity and neuronal degeneration. FASEB J 15:1858–1860PubMedGoogle Scholar
  67. 67.
    Meertens L, Zhao Y, Rosic-Kablar S et al (2002) In utero injection of alpha-L-iduronidase-carrying retrovirus in canine mucopolysaccharidosis type I: infection of multiple tissues and neonatal gene expression. Hum Gene Ther 13:1809–1820PubMedCrossRefGoogle Scholar
  68. 68.
    Messina C, Rampazzo A, Cesaro S et al (2008) Eighteen-year follow-up of the first Italian MPSI patient treated with bone marrow transplantation. Bone Marrow Transplant 41:905–906PubMedCrossRefGoogle Scholar
  69. 69.
    Hartung SD, Frandsen JL, Pan D et al (2004) Correction of metabolic, craniofacial, and neurologic abnormalities in MPS I mice treated at birth with adeno-associated virus vector transducing the human alpha-L-iduronidase gene. Mol Ther 9:866–875PubMedCrossRefGoogle Scholar
  70. 70.
    Visigalli I, Delai S, Politi LS et al. (2010) Gene therapy augments the efficacy of hematopoietic cell transplantation and fully corrects Mucopolysaccharidosis type I phenotype in the mouse model. BloodGoogle Scholar
  71. 71.
    Wang D, Zhang W, Kalfa TA et al (2009) Reprogramming erythroid cells for lysosomal enzyme production leads to visceral and CNS cross-correction in mice with Hurler syndrome. Proc Natl Acad Sci U S A 106:19958–19963PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Karie A. Heinecke
    • 1
  • Brandon N. Peacock
    • 2
  • Bruce R. Blazar
    • 2
  • Jakub Tolar
    • 2
  • Thomas N. Seyfried
    • 1
  1. 1.Department of BiologyBoston CollegeBostonUSA
  2. 2.Department of PediatricsUniversity of MinnesotaMinneapolisUSA

Personalised recommendations